Abstract
The detection of minimal residual disease (MRD) in patients with acute leukemia has been studied for about 15 years by different groups in both the United States and Europe. It has been found that MRD detection can be performed using molecular and immunophenotypic aberrancies that are present in the leukemic clone at diagnosis and not in normal bone marrow. When performing MRD assessments after chemotherapy, it is possible to identify patients at risk for relapse. This review is not an overview of all MRD studies, but rather discusses the possibilities for optimizing MRD detection, the use of flow cytometry versus polymerase chain reaction techniques, and the implications for future patient treatment. When informative, we compare literature on MRD in acute myeloid leukemia (AML) with information from MRD studies in acute lymphoblastic leukemia. Finally, we address the promising detection of AML stem cells, the likely cells of origin in AML, for prediction of clinical outcome and guidance of future therapies.
Article PDF
Similar content being viewed by others
References and Recommended Reading
Ries LAG, Harkins D, Krapcho M, et al.: SEER Cancer Statistics Review, 1975–2003. Bethesda, MD: National Cancer Institute; 2006. Available at http://seer.cancer.gov/csr/1975_2003/
Lowenberg B, Griffin JD, Tallman MS: Acute myeloid leukemia and acute promyelocytic leukemia [review]. Hematology Am Soc Hematol Educ Program 2003, 82–101.
Legrand O, Simonin G, Perrot JY, et al.: Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients. Blood 1998, 91:4480–4488.
van der Pol MA, Feller N, Ossenkoppele GJ, et al.: Minimal residual disease in acute myeloid leukemia is predicted by P-glycoprotein activity but not by multidrug resistance protein activity at diagnosis. Leukemia 2003, 17:1674–1677.
Del Poeta G, Venditti A, Del Principe MI, et al.: Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). Blood 2003, 101:2125–2131.
van Stijn A, Feller N, Kok A, et al.: Minimal residual disease in acute myeloid leukemia is predicted by an apoptosis-resistant protein profile at diagnosis. Clin Cancer Res 2005, 11:2540–2546.
Matsunaga T, Takemoto N, Sato T, et al.: Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med 2003, 9:1158–1165.
De Toni F, Racaud-Sultan C, Chicanne G, et al.: A crosstalk between the Wnt and the adhesion-dependent signaling pathways governs the chemosensitivity of acute myeloid leukemia. Oncogene 2006, 25:3113–3122.
Kokenberg E, Sonneveld P, Sizoo W, et al.: Cellular pharmacokinetics of daunorubicin: relationships with the response to treatment in patients with acute myeloid leukemia. J Clin Oncol 1988, 6:802–812.
Gessner T, Preisler HD, Azarnia N, et al.: Plasma levels of daunorubicin metabolites and the outcome of ANLL therapy. Med Oncol Tumor Pharmacother 1987, 4:23–31.
Bonnet D, Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997, 3:730–737.
Costello RT, Mallet F, Gaugler B, et al.: Human acute myeloid leukemia CD34+/CD38− progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities. Cancer Res 2000, 60:4403–4411.
Bacher U, Schnittger S, Kern W, et al.: Acute myeloid leukemia (AML) with t(8;21)(q22;q22) relapsing as AML with t(3;21)(q26;q22). Cancer Genet Cytogenet 2006, 168:172–174.
van Rhenen A, Feller N, Kelder A, et al.: High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res 2005, 11:6520–6527.
Campana D: Minimal residual disease studies in acute leukemia. Am J Clin Pathol 2004, 122(Suppl):S47–S57.
Vidriales MB, Perez JJ, Lopez-Berges MC, et al.: Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value. Blood 2003, 101:4695–4700.
Coustan-Smith E, Sancho J, Hancock ML, et al.: Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 2000, 96:2691–2696.
van Dongen JJ, Seriu T, Panzer-Grumayer ER, et al.: Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998, 352:1731–1738.
Sievers EL, Lange BJ, Alonzo TA, et al.: Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children’s Cancer Group study of 252 patients with acute myeloid leukemia. Blood 2003, 101:3398–3406.
Coustan-Smith E, Ribeiro RC, Rubnitz JE, et al.: Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia. Br J Haematol 2003, 123:243–252.
San Miguel JF, Vidriales MB, Lopez-Berges C, et al.: Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood 2001, 98:1746–1751.
Venditti A, Buccisano F, Del Poeta G, et al.: Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood 2000, 96:3948–3952.
Feller N, van der Pol MA, van Stijn A, et al.: MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia. Leukemia 2004, 18:1380–1390.
Kern W, Voskova D, Schoch C, et al.: Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood 2004, 104:3078–3085.
Kern W, Schoch C, Haferlach T, Schnittger S: Monitoring of minimal residual disease in acute myeloid leukemia. Crit Rev Oncol Hematol 2005, 56:283–309.
Baer MR, Stewart CC, Dodge RK, et al.: High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361). Blood 2001, 97:3574–3580.
Kern W, Danhauser-Riedl S, Ratei R, et al.: Detection of minimal residual disease in unselected patients with acute myeloid leukemia using multiparameter flow cytometry for definition of leukemia-associated immunophenotypes and determination of their frequencies in normal bone marrow. Haematologica 2003, 88:646–653.
Roederer M, De Rosa S, Gerstein R, et al.: 8 color, 10-parameter flow cytometry to elucidate complex leukocyte heterogeneity. Cytometry 1997, 29:328–339.
Voskova D, Schnittger S, Schoch C, et al.: Use of five-color staining improves the sensitivity of multiparameter flow cytomeric assessment of minimal residual disease in patients with acute myeloid leukemia. Leuk Lymphoma 2007, In press.
Schnittger S, Weisser M, Schoch C, et al.: New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts. Blood 2003, 102:2746–2755.
Guerrasio A, Pilatrino C, De Micheli D, et al.: Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts. Leukemia 2002, 16:1176–1181.
Gallagher RE, Yeap BY, Bi W, et al.: Quantitative real-time RT-PCR analysis of PML-RAR alpha mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129. Blood 2003, 101:2521–2528.
Grimwade D, Walker H, Oliver F, et al.: The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children’s Leukaemia Working Parties. Blood 1998, 92:2322–2333.
van Dongen JJ, Macintyre EA, Gabert JA, et al.: Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 1999, 13:1901–1928.
Schnittger S, Schoch C, Dugas M, et al.: Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002, 100:59–66.
Cloos J, Goemans BF, Hess CJ, et al.: Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples. Leukemia 2006, 20:1217–1220.
Burmeister T, Marschalek R, Schneider B, et al.: Monitoring minimal residual disease by quantification of genomic chromosomal breakpoint sequences in acute leukemias with MLL aberrations. Leukemia 2006, 20:451–457.
Falini B, Mecucci C, Tiacci E, et al.: Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005, 352:254–266.
Gorello P, Cazzaniga G, Alberti F, et al.: Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. Leukemia 2006, 20:1103–1108.
Karakas T, Miething CC, Maurer U, et al.: The coexpression of the apoptosis-related genes bcl-2 and wt1 in predicting survival in adult acute myeloid leukemia. Leukemia 2002, 16:846–854.
Weisser M, Kern W, Rauhut S, et al.: Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia. Leukemia 2005, 19:1416–1423.
Kreuzer KA, Saborowski A, Lupberger J, et al.: Fluorescent 5′-exonuclease assay for the absolute quantification of Wilms’ tumour gene (WT1) mRNA: implications for monitoring human leukaemias. Br J Haematol 2001, 114:313–318.
Barjesteh van Waalwijk van Doorn-Khosrovani S, Erpelinck C, van Putten WL, et al.: High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood 2003, 101:837–845.
Steinbach D, Hermann J, Viehmann S, et al.: Clinical implications of PRAME gene expression in childhood acute myeloid leukemia. Cancer Genet Cytogenet 2002, 133:118–123.
Paydas S, Tanriverdi K, Yavuz S, et al.: PRAME mRNA levels in cases with acute leukemia: clinical importance and future prospects. Am J Hematol 2005, 79:257–261.
Kerst G, Kreyenberg H, Roth C, et al.: Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR. Br J Haematol 2005, 128:774–782.
Malec M, Bjorklund E, Soderhall S, et al.: Flow cytometry and allele-specific oligonucleotide PCR are equally effective in detection of minimal residual disease in ALL. Leukemia 2001, 15:716–727.
Perea G, Lasa A, Aventin A, et al.: Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)]. Leukemia 2006, 20:87–94.
Gianfaldoni G, Mannelli F, Baccini M, et al.: Clearance of leukaemic blasts from peripheral blood during standard induction treatment predicts the bone marrow response in acute myeloid leukaemia: a pilot study. Br J Haematol 2006, 134:54–57.
Goulden N, Virgo P, Grimwade D: Minimal residual disease directed therapy for childhood acute myeloid leukaemia: the time is now. Br J Haematol 2006, 134:273–282.
Leroy H, de Botton S, Grardel-Duflos N, et al.: Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21). Leukemia 2005, 19:367–372.
Coustan-Smith E, Sancho J, Hancock ML, et al.: Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia. Blood 2002, 100:2399–2402.
van der Velden V, Jacobs DC, Wijkhuijs AJ, et al.: Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL. Leukemia 2002, 16:1432–1436.
Breccia M, Diverio D, Noguera NI, et al.: Clinico-biological features and outcome of acute promyelocytic leukemia patients with persistent polymerase chain reaction-detectable disease after the AIDA front-line induction and consolidation therapy. Haematologica 2004, 89:29–33.
Hess CJ, Feller N, Denkers F, et al.: Immunophenotypical minimal residual disease as a short term endpoint for monitoring effects of targeted inhibitors in acute myeloid leukemia [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:Abstract 545.
Jordan CT, Upchurch D, Szilvassy SJ, et al.: The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 2000, 14:1777–1784.
Taussig DC, Pearce DJ, Simpson C, et al.: Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood 2005, 4086–4092.
Bakker AB, Van den Oudenrijn S, Bakker AQ, et al.: C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia. Cancer Res 2004, 64:8443–8450.
van Rhenen A, Feller N, Kelder A, et al.: The novel AML stem cell associated antigen CLL-1 discriminates between normal and leukemic stem cells [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:Abstract 4.
van Rhenen A, Feller N, Kelder A, et al.: In acute myeloid leukemia both malignant and normal stem cells can be detected in remission bone marrow [abstract]. Blood (ASH Annual Meeting Abstracts) 2006, 108:Abstract 2537.
Goodell MA, Brose K, Paradis G, et al.: Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 1996, 183:1797–1806.
Goodell MA, Rosenzweig M, Kim H, et al.: Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. Nat Med 1997, 3:1337–1345.
Wulf GG, Wang RY, Kuehnle I, et al.: A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood 2001, 98:1166–1173.
Moshaver B, Feller N, Kelder A, et al.: The side population may provide the leukemic stem cell compartment complementary to the CD34+CD38-stem cell compartment. Implications for stem cell MRD detection and therapeutic targeting [abstract]. Haematologica 2006, 91:321.
Moshaver B, van der Pol MA, Westra GH, et al.: Identification of primitive subpopulations of acute myeloid leukemia side population (SP) stem cells defined by differentiation status and malignant character [abstract]. Blood (ASH Annual Meeting Abstracts) 2006, 108:Abstract 2538.
Moshaver B, van der Pol MA, Westra G, et al.: Acute myeloid leukemia remssion bone marrow reveals the presence of malignant and normal side population (SP) stem cells whose frequencies and ratios predict clinical outcome [abstract]. Blood (ASH Annual Meeting Abstracts) 2006, 108:Abstract 2314.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This is an open access article distributed under the terms of the Creative Commons Attribution Noncommercial License ( https://creativecommons.org/licenses/by-nc/2.0 ), which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
About this article
Cite this article
van Rhenen, A., Moshaver, B., Ossenkoppele, G.J. et al. New approaches for the detection of minimal residual disease in acute myeloid leukemia. Curr Hematol Malig Rep 2, 111–118 (2007). https://doi.org/10.1007/s11899-007-0016-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11899-007-0016-0